HiCore resin Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is a cross-linked, water-insoluble polyelectrolyte resin supplied under route-specific oral-grade and injectable-grade designations. The API designation places the material under ICH Q7 controls and, when formulated into registered finished dosage forms, under 21 CFR 210/211 requirements. Product release includes identity by infrared spectrophotometry aligned to USP <197>, loss on drying by USP <731>, residue on ignition by USP <281>, particle size distribution by laser diffraction aligned to USP <429>, and elemental impurity determination by USP <232>/USP <233> with limits derived from ICH Q3D. The injectable-grade designation adds bacterial endotoxin testing by USP <85>, sterility by USP <71>, and subvisible particulate matter by USP <788>. Route-specific milled or sieved fractions are assigned by the manufacturer because no single particle size profile is suitable for tablet compression, capsule filling, granulation, and parenteral dispersion.

The model identifier HiCore resin Pharma Grade API is further split into oral solid-dose and injectable subgrades by the manufacturer. The oral-grade powder is provided with controlled bioburden but is not sterile; the injectable-grade powder is supplied as a sterile, depyrogenated powder with endotoxin control. Because the resin is insoluble and cross-linked, it does not dissolve in gastrointestinal fluid or water for injection; it is dispersed as a suspension rather than a solution. This physical form has implications for syringe gauge selection in parenteral administration and for dissolution testing in oral products. The manufacturer’s certificate of analysis for injectable grade includes loss on drying, residue on ignition, particle size distribution, bacterial endotoxins, and sterility; the oral grade certificate includes microbial enumeration and specified organisms rather than sterility.

Analytical methods are qualified according to ICH Q2(R1) for identity, exchange capacity, residual solvent, and elemental impurity procedures. For particle size distribution by laser diffraction, the method is aligned to USP <429>; for sieve analysis, the method is aligned to USP <786>. The laser diffraction method uses wet dispersion in a non-swelling carrier to avoid particle size bias caused by resin swelling. Optical models require refractive index values for the resin backbone; if the optical constants are not published, method development includes iterative fitting with a laser diffraction instrument equipped with a liquid dispersion unit. This level of method control is part of the difference between pharmaceutical-grade and technical-grade material.

For tablet and capsule manufacture, HiCore resin Pharma Grade API is blended before direct compression, dry granulation, or wet granulation. Powder flow is evaluated using USP <1174>, bulk and tapped density using USP <616>, and compressibility is measured on instrumented rotary tablet presses. Production-scale rotary presses equipped with forced feeders exhibit die fill variation when the D50 shifts by more than 15 µm; therefore particle size is controlled as a release parameter. The powder is conditioned to room temperature and protected from humidity above 60% relative humidity because moisture uptake alters loss on drying and flow. Dry granulation by roller compaction may be used to densify the material, but excessive compaction pressure fractures resin beads and increases fines. Tablet hardness is evaluated by USP <1217>, friability by USP <1216>, disintegration by USP <701>, and dissolution by USP <711>.

On a rotary tablet press, precompression force and main compression force are recorded; the resin can be compacted at main compression forces in the range of 5 kN to 20 kN depending on tablet diameter and formulation. Tablet press speed is set to avoid capping and lamination because air entrapment is common in resin powders with small bead size. The powder is blended in a bin blender at 10–15 rpm for 10 min after geometric dilution with the active pharmaceutical ingredient; over-blending may generate fines by attrition. Content uniformity is evaluated by USP <905>. Published data for this specific configuration is limited; however, direct compression resin materials commonly target a D50 between 75 µm and 150 µm to balance flow and compactability.

What Distinguishes HiCore Resin from Non-Pharmaceutical Ion-Exchange Grades?

The pharmaceutical grade is differentiated by the depth of extractables, leachables, bioburden, elemental impurity, and residual monomer data generated under the manufacturing license. Technical-grade ion-exchange resins may share the same backbone chemistry but are not manufactured under ICH Q7, are not tested by compendial methods for endotoxin and specified organisms, and are not accompanied by a drug master file. Residual solvents are controlled by USP <467> with headspace gas chromatography; where mutagenic impurities are plausible, limits are aligned to ICH M7. For injectable use, extractables are evaluated according to USP <1663> and leachables according to USP <1664>. The oral solid-dose grade may be qualified by systemic toxicity risk assessment rather than full parenteral extractables testing. The resulting difference is not monomer identity but the analytical closure and route-specific acceptance limits.

In contrast to soluble polymers used as matrix formers, HiCore resin Pharma Grade API remains undissolved and provides release modification through ionic interaction, not through polymer dissolution or gel-layer formation. This distinction affects dissolution method development: USP <701> disintegration and USP <711> dissolution may require media containing defined concentrations of competing cations to discriminate product performance. The resin is not a simple filler-binder; its batch release includes exchange capacity and residual functional group tests that are not part of microcrystalline cellulose or lactose monographs. Specifications therefore include both pharmacopeial general chapters and manufacturer-specific tests for bound counterion content, swelling volume, and residual monomer profile.

When the Injectable Route Requires Endotoxin and Particulate Control

The injectable presentation is controlled as a sterile, depyrogenated powder intended for dispersion in an aqueous vehicle. Release is performed against the finished suspension when the powder is reconstituted, because particulate matter in the dry powder is not a meaningful measurement. Endotoxin limits are derived from the maximum daily dose and the route-specific threshold in USP <85>. If terminal steam sterilization is used, the cycle is validated according to ISO 17665 or USP <1229.1> for the specific load configuration. Resin hydration can alter packed-bed volume and settling rate; therefore the reconstituted suspension is characterized for resuspendability, viscosity, and syringeability. A rotational viscometer at 25 °C and a defined shear rate is used to measure suspension viscosity. Autoclaving may release low levels of leachables; the terminal sterilized suspension should be re-profiled for extractables by USP <1663>. Dry heat sterilization at 160 °C for 2 h is not recommended unless validated, because organic ion-exchange resins can degrade and discolor. Gamma irradiation at 25 kGy may generate free radicals in styrene-divinylbenzene backbones, altering swelling capacity and extractables; dose mapping and post-irradiation extractables profiling are required.

Extractable profiling for injectable grade is conducted by reflux or Soxhlet extraction followed by gas chromatography–mass spectrometry and liquid chromatography–mass spectrometry under conditions described in USP <1663>. Leachables studies for the finished injection use the actual container closure system and are supported by USP <1664>. The analytical threshold is based on the daily dose and the qualification threshold for parenteral products; data are reported as total organic carbon and specific organic compounds. The resin is incompatible with strong oxidizing agents and with some amine-based additives because of the risk of redox reactions or displacement of exchangeable counterions. These incompatibilities are stated in the manufacturer’s technical data.

Production-scale drying of the injectable grade is performed under a laminar-flow zone after depyrogenation of contact parts; transfer lines are dedicated to the injectable grade to prevent cross-contamination from nonsterile oral materials. The resin is filled into sterilized containers under controlled particle counts, and air-sampling data are part of the batch record. This control strategy is required because the material is a particulate suspension, not a solution, and sterility assurance cannot rely on terminal filtration.

Tablet, Capsule, and Granule Processing Parameters

In wet granulation, the resin is blended with a granulating fluid; because the material swells, the liquid-to-solid ratio is kept below the point of bead rupture. Granule size distribution is measured by USP <786> sieve analysis. High-shear granulator impeller speed and liquid addition rate are developed through design of experiments. Tray drying is monitored by loss on drying using USP <731>; residual moisture above 3.0% w/w may reduce tablet hardness and increase sticking on steel tooling. Direct compression formulations are preferred when the particle size distribution is sufficiently narrow. In capsule filling on dosator machines, plug weight is sensitive to powder bulk density and D50 drift. Roller compaction may be used to improve flow; compaction pressure must be limited to avoid bead fracture. Dissolution testing by USP <711> should be performed in pH-shift media if the dosage form is an enteric-coated multiparticulate.

When wet granulation is used, the resin is first dry mixed with the active pharmaceutical ingredient for 5 min in a high-shear granulator with the impeller at low speed, then granulating fluid is added at 2–5% w/w/min until the endpoint. The endpoint is determined by impeller torque and visual observation; over-granulation causes resin beads to rupture and can increase dissolution variability. The wet mass is passed through a 1.0 mm screen and dried at 40–50 °C to a final moisture content not more than 3.0% w/w. Milling of dried granules through a 0.8 mm screen is used to normalize granule size before compression or capsule filling.

Roller compaction is performed on a roller compactor with roll pressure between 30 bar and 70 bar, roll speed, and screen size as variables. The ribbon density is measured before milling; a target ribbon solid fraction between 0.55 and 0.75 is used to balance granule strength and tablet compactability. These ranges are starting points and are optimized with the formulation composition.

In oral suspension systems, HiCore resin Pharma Grade API is dispersed with suspending agents, preservatives, and ionic strength modifiers. Sedimentation volume and redispersibility are measured after defined shaking cycles, and viscosity is measured by a rotational viscometer at 25 °C. Drug-resin complex formation is affected by pH and competing ions; therefore equilibrium binding studies are conducted in simulated gastric fluid and simulated intestinal fluid at 37 °C. The pH of the final suspension is selected to maintain the desired degree of ionization without exceeding the resin’s swelling threshold.

Residual solvent control follows USP <467> Option 1 or 2; headspace sampling is matched to the solvent vapor pressure of the resin bed. Direct aqueous injection is not suitable because the resin swells. For nonsterile oral grades, microbial enumeration by USP <61> and specified organisms by USP <62> are applied with acceptance criteria aligned to USP <1111>. Packaging in double polyethylene bags inside fiber drums protects against moisture and physical damage during storage.

Stability programs follow ICH Q1A(R2) and ICH Q1E for the intended dosage form. Accelerated conditions at 40 °C/75% relative humidity evaluate moisture uptake and particle aggregation. Photostability is assessed per ICH Q1B using 1.2 million lux hours visible and 200 W h/m² near-ultraviolet exposure for injectable grade. Release and stability data are trended for loss on drying, particle size distribution, exchange capacity, and extractables. The material is not a terminal-sterilized product unless the specific lot is released as sterile injectable grade with the appropriate certificate of analysis.